Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pimecrolimus
Drug ID BADD_D01773
Description Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Indications and Usage For treatment of mild to moderate atopic dermatitis.
Marketing Status approved; investigational
ATC Code D11AH02
DrugBank ID DB00337
KEGG ID D05480
MeSH ID C117268
PubChem ID 6447131
TTD Drug ID D0Z4UN
NDC Product Code 55486-1585; 68682-112; 62227-004; 68254-0014; 0187-5102; 0591-2944; 62227-024; 65727-045; 0187-5101; 53296-0115; 0187-5100; 68682-110; 68462-609; 68682-111; 51552-1620; 16436-0115; 0187-5103
UNII 7KYV510875
Synonyms pimecrolimus | 33-epi-chloro-33-desoxyascomycin | SDZ ASM 981 | SDZ-ASM-981 | ASM 981 | Elidel
Chemical Information
Molecular Formula C43H68ClNO11
CAS Registry Number 137071-32-0
SMILES CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C 4)OC)Cl)C)O)C)OC)OC)C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Headache17.14.01.001--
Herpes simplex23.11.05.004; 11.05.02.001--Not Available
Hodgkin's disease16.31.01.001; 01.16.01.0010.000466%Not Available
Hypersensitivity10.01.03.003--
Immune system disorder10.02.01.001--Not Available
Impetigo23.11.02.011; 11.01.12.006--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Insomnia19.02.01.002; 17.15.03.0020.000466%
Leukaemia01.10.03.001; 16.01.03.001--
Leukoderma23.05.02.001--Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Malaise08.01.01.0030.000700%
Malignant histiocytosis16.21.04.001; 01.13.04.001--Not Available
Malignant melanoma16.03.01.001; 23.08.01.001--Not Available
Molluscum contagiosum23.11.05.007; 11.05.12.001--Not Available
Nasal congestion22.04.04.001--
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.001--Not Available
Neoplasm skin23.08.02.003; 16.03.02.003--Not Available
Nervous system disorder17.02.10.001--Not Available
Nightmare19.02.03.0030.000466%Not Available
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.001--Not Available
Ocular hyperaemia06.04.05.0040.001026%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.004--
Paraesthesia23.03.03.094; 17.02.06.0050.000466%
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages